Transforming growth factor-β (TGFβ) isoforms are upregulated and activated in myocardial
diseases and have an important role in cardiac repair and remodelling, regulating the …

Heart failure with preserved ejection fraction (HFpEF) affects half of all patients with heart
failure worldwide, is increasing in prevalence, confers substantial morbidity and mortality …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Obesity and heart failure with preserved ejection fraction (HFpEF) represent two
intermingling epidemics driving perhaps the greatest unmet health problem in …

Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous
clinical syndrome affected in its development and progression by many comorbidities. The …

Endothelial dysfunction represents a key mechanism underlying heart failure with preserved
ejection fraction (HFpEF), diabetes mellitus (DM), and frailty. However, reliable biomarkers …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the composite of
heart failure (HF) hospitalizations or cardiovascular mortality among patients with HF …

In patients with diabetes, myocardial fibrosis may contribute to the pathogenesis of heart
failure and arrhythmogenesis, increasing ventricular stiffness and delaying conduction …

Heart failure (HF) is a complex syndrome that affects approximately 6.5 million adults in the
United States. About half of the 6.5 million adults with HF are estimated to be individuals with …

Background: Empagliflozin improves outcomes in patients with heart failure with a preserved
ejection fraction, but whether the effects are consistent in patients with and without diabetes …